Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230334 · ClinicalTrials.gov registry record · Phase 2
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
A Phase 2 study, sponsored by Steven E. Coutre.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00230334: Clinical Trial Phase 2 study, sponsored by Steven E. Coutre.
NCT00230334 is a Phase 2 study that was terminated before completion, run by Steven E. Coutre. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00230334, a Phase 2 study, was terminated before completion, sponsored by Steven E. Coutre.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
Interventions
- DRUG Gleevec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2003-06-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Why NCT00230334 stopped before completion
NCT00230334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Gleevec is the first listed.
NCT00230334 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00230334 about?
NCT00230334 is a clinical study titled "Phase II Gleevec Idiopathic Hypereosinophilic Syndrome". The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
What is the current status of trial NCT00230334?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2003-06-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00230334?
The interventions under investigation include: Gleevec (DRUG).
Who is sponsoring clinical trial NCT00230334?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00230334's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI